BioIVT promotes Dr. Richard Haigh to CEO

BioIVT, a global provider of biospecimens, cell & gene therapy related products, and research models and services for drug development purposes, has promoted Richard Haigh, PhD, to Chief Executive Officer (CEO).

Dr. Haigh joined BioIVT in May 2022 as Chief Operating Officer and brings over 27 years’ experience in the life science research and diagnostics space covering products, consumables, and services, including over 15 years with Thermo Fisher Scientific/Life Technologies.  

Former CEO Jeff Gatz has retired from day-to-day involvement with BioIVT but will continue to support the company as an advisor focused on M&A and business development activities. Over the last 26 years, Gatz has successfully led and grown the business from a small family operation to a global enterprise employing over 500 people and serving thousands of pharma, biotech, CRO and diagnostic customers worldwide.